A carregar...
A phase II trial of capecitabine (Xeloda®) in recurrent ovarian cancer
Oral capecitabine is a highly active, well-tolerated and convenient treatment for breast and colorectal cancer. This trial assessed the efficacy and safety of single-agent capecitabine in patients with previously treated ovarian cancer. A total of 29 patients with platinum-pretreated relapsed ovaria...
Na minha lista:
| Main Authors: | , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Nature Publishing Group
2003
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2394434/ https://ncbi.nlm.nih.gov/pubmed/14612890 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6601381 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|